Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients
- 30 November 2004
- journal article
- other
- Published by Elsevier in Joint Bone Spine
- Vol. 71 (6) , 601-603
- https://doi.org/10.1016/j.jbspin.2004.07.009
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Switching between anti-TNFα agents: what is the evidence?Joint Bone Spine, 2004
- Factors predicting responsiveness to anti-TNFα therapy in patients with rheumatoid arthritis: using biotherapies rationallyJoint Bone Spine, 2004
- Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make senseAnnals of the Rheumatic Diseases, 2003
- Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot studyClinical Therapeutics, 2003
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988